PRAX · Healthcare · $8.1B
$289.92-0.45%
What's this stock's score right now?
See its score for free — revenue and money flow, graded on one standard.
Quarterly Financials
9/'26
6/'26 vs prev quarter
Among 464 Biotechnology peers
Quarterly Revenue Growth
“아직 매출은 0원이지만 상업화 준비가 실제로 진행 중이에요 — 두 개 신약(ulixacaltamide, relutrigine)이 FDA 승인 심”
In the company's words · 2026 2분기 earnings call